The mechanisms of reperfusion during in stroke patients treated with intravenous thrombolysis
https://doi.org/10.14412/2074-2711-2012-422
Abstract
Systemic (intravenous) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is a proved effective treatment modality in a certain group of patients with ischemic stroke (IS) in the first 4.5 hours after the onset of neurological symptoms. The main mechanism for improving functional outcomes in patients treated with intravenous thrombolysis is reperfusion of an ischemic brain portion. The results of intravenous thrombolytic therapy are shown in 60 IS patients (18 women and 42 men; mean age 61 years). Different mechanisms of reperfusion during systemic thrombolysis, which are not confined to thrombus- or embolus-occluded artery recanalization, but are a portrait of the systemic effect of the thrombolytic drug and include collateral blood flow activation, gradual recanalization, etc.
About the Authors
Maksim Alekseyevich DomashenkoM Yu Maksimova
M A Loskutnikov
A A Nikonov
V V Bryukhov
A S Suslin
M V Dreval
R N Konovalov
References
1. <div><p>Инсульт: диагностика, лечение, профилактика. Под ред. З.А. Суслиной, М.А. Пира-дова. М.: МЕДпресс-информ, 2008;288 с.</p><p>Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения. М.: МИА, 2009; 224 с.</p><p>Adams H., Del Zoppo G., Alberts M. et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007;38:1655-711.</p><p>Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for prevention of stroke in patients with stroke or transient ischemic attack. Stroke 2011;42:227-76.</p><p>Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008/2009 http://www.eso-stroke.org/recommendations</p><p>Hacke W., Kaste M., Fieschi C. et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.</p><p>The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.</p><p>Hacke W., Kaste M., Fieschi C. et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.</p><p>Clark W.M., Wissman S., Albers G.W. et al. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999;282 (21):2019-26.</p><p>Hacke W., Kaste M., Bluhmki E. et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008;359(13):1317-29.</p><p>Wardlaw J.M., Zoppo G., Jamaguchi T. et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; CD000213</p><p>Hacke W., Donnan G., Fieschi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.</p><p>Lees K.R., Bluhmki E., von Kummer R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.</p><p>Wahlgren N., Anmed N., Davalos A. et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SIST-MOST): an observational study. Lancet 2007;369:275-82.</p><p>Ahmed N., Wahlgren N., Grond M. et al. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010;9:866-74.</p><p>Rha J-H., Saver J.L. The Impact of Recanalization on Ischemic Stroke Outcome. A Meta-Analysis. Stroke 2007;38:967-73.</p><p>Домашенко М.А., Максимова М.Ю., Суслина З.А. Возможности медикаментозного тромболизиса в лечении пациентов с ишемическим инсультом. Фарматека 2009;7:38-44.</p><p>Домашенко М.А., Максимова М.Ю., Кротенкова М.В. и др. Способ определения показаний для проведения внутривенной тромболитической терапии в остром периоде ишемического инсульта. Патент на изобретение №2444990 (зарегистрирован в Государственном реестре изобретений РФ 20.03.2012).</p><p>Ginsberg M.D. Visualising the cortical microcirculation in patients with stroke. Crit Care Med 2011;39:1228-30.</p><p>Dalkara T., Arsava E. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis? J Cereb Blood Flow Metab 2012 (epub 12 Oct)</p><p>Furlan A., Higashida R., Wechsler L. et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282(21):2003-11.</p><p>http://www.ninds.nih.gov/disorders/clinical_trials/IMS-III.htm</p></div><br />
Review
For citations:
Domashenko MA, Maksimova MY, Loskutnikov MA, Nikonov AA, Bryukhov VV, Suslin AS, Dreval MV, Konovalov RN. The mechanisms of reperfusion during in stroke patients treated with intravenous thrombolysis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(4):53-58. (In Russ.) https://doi.org/10.14412/2074-2711-2012-422
Views: 715
Email this article 